Skip to main content
Back
ASCLF logo

Ascletis Pharma Inc.

Data quality: 100%
Oversold
ASCLF
OTC Healthcare Biotechnology
$1.81
$0.00 (0.00%)
Mkt Cap: 1.91B
Day Range
$1.81 $1.90
52-Week Range
$0.62 $2.29
Volume
9,000
50D / 200D Avg
$1.91 / $1.58
Prev Close
$1.81

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -6.4 0.4
P/B 1.0 2.9
ROE % -14.0 3.8
Net Margin % -23455.7 3.9
Rev Growth 5Y % -56.2 10.0
D/E 0.0 0.2

Analyst Price Target

No analyst coverage available

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$0.37
-$0.37 – -$0.37
39 M 1
FY2026 $0.90
$0.90 – $0.90
1.3 B 1

Key Takeaways

Revenue declined -56.24% annually over 5 years
Debt/Equity of 0.00 — conservative balance sheet
Negative free cash flow of -343.73M
Revenue growth is decelerating — 1Y growth trails 5Y average by 41.49%
Capital intensive — 167.42% of revenue goes to capex

Growth

Revenue Growth (5Y)
-56.24%
Revenue (1Y)-97.73%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-13.97%
ROIC-11.23%
Net Margin-23455.65%
Op. Margin-23025.64%

Safety

Debt / Equity
0.00
Current Ratio12.88
Interest Coverage0.00

Valuation

P/E Ratio
-6.35
P/B Ratio0.97
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -97.73% Revenue Growth (3Y) -84.60%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -56.24% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.28M Net Income (TTM) -300.94M
ROE -13.97% ROA -14.16%
Gross Margin 57.29% Operating Margin -23025.64%
Net Margin -23455.65% Free Cash Flow (TTM) -343.73M
ROIC -11.23% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.00 Current Ratio 12.88
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -6.35 P/B Ratio 0.97
P/S Ratio 1488.83 PEG Ratio -0.04
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 1.91B Enterprise Value 1.05B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1.28M 56.60M 54.09M 76.88M 35.00M
Net Income -300.94M -144.72M -314.84M -199.02M -209.24M
EPS (Diluted) -0.30 -0.13 -0.29 -0.18 -0.20
Gross Profit 735,000.0 25.99M -24.69M 39.17M -23.50M
Operating Income -295.42M -300.21M -343.98M -224.97M -217.11M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 2.12B 2.49B 2.66B 2.83B 3.07B
Total Liabilities 158.41M 148.94M 117.16M 100.89M 85.42M
Shareholders' Equity 1.97B 2.34B 2.54B 2.73B 2.98B
Total Debt 7.63M 8.42M 4.24M 2.75M 1.59M
Cash & Equivalents 865.73M 330.12M 2.47B 2.50B 2.71B
Current Assets 1.97B 2.33B 2.54B 2.63B 2.83B
Current Liabilities 153.05M 140.68M 108.19M 90.97M 73.77M